David Mack is the creator, author and artist of KABUKI published originally by Image Comics and now through Marvel Comics’ imprint ICON. He is also the writer and artist of Daredevil (one of the top ten best selling comics in the United States) from Marvel Comics.
Mack's work has garnered nominations for two 1999 International Eagle Awards in the categories of Favorite Comic Artist (Painted), and Best Cover Art of the Year (Painted), the Eisner Awards in the category of Best Painter, and both the Harvey and Kirby awards in the category of Best New Talent, as well as other awards and nominations.
KABUKI, has earned David international acclaim for its innovative storytelling, painting techniques, and page design. It is available in seven different languages in addition to well over a million copies of KABUKI Comics, Paperbacks, and Hardcovers in print in the U.S. alone. Mack has toured and exhibited throughout, Europe, Asia, and America. He was the first American to be nominated for Germany's most prestigious Max-Und-Moritz award in the category of best-imported comic.
David did not attend a specialized art school, but earned a full scholarship to a University for five years. There, he studied multiple disciplines in art and academics, including World History, Anatomy & Physiology and the Japanese Language. He graduated with a BFA in Graphic Design and a Minor in English. His books have been the subject of under-graduate and graduate university coursed in Art and Literature, and listed as required reading. His work has been studied in graduate seminars at USC and hung in the Los Angeles Museum of Art.
Mack has designed toys and packaging for companies in Hong Kong, created ad campaigns for Sakura art materials and illustrated Jazz and Rock albums for Japanese and American labels and musicians such as Paul McCartney.
Currently, David is working on the live action Kabuki feature film for 20th Century Fox. Besides writing the treatment, his credits include: Visual Designer, Creative Consultant and Co-Producer.
No comments:
Post a Comment